New drug targets for the treatment of gout arthritis: What's new?

In our search, we observed that there is a massive gap between pre-clinical and clinical knowledge. Only a minority (4.4%) of clinical trials aimed to intervene applying natural products, or current hot targets described herein. In this sense, we envisage four possibilities for GA therapeutics, which includes the repurposing of existing therapies, ALX/FPR2 agonism for improvement in disease outcome, the use of multitarget drugs (e.g. natural products), and targeting the neuroinflammatory component of GA.